Anavex Life Sciences (AVXL) 8-K Regulation FD Disclosure

ANAVEX LIFE SCIENCES CORP.
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS
September 15, 2015 and September 30, 2014
(Unaudited)

ASSETS

		September 15,		September 30,
		2015		2014
Current
Cash	$	13,101,846	$	7,262,138
Prepaid expenses		79,321		89,117
Total current assets		13,181,167		7,351,255
Equipment		1,501		2,247
Total assets	$	13,182,668	$	7,353,502

LIABILITIES

Current
Accounts payable and accrued liabilities	$	1,016,369	$	1,249,084
Promissory notes payable		92,516		192,065
Total current liabilities		1,108,885		1,441,149
Non-interest bearing liabilities		436		5,719,727
Total liabilities		1,109,321		7,160,876

STOCKHOLDERS' EQUITY

Capital stock
Authorized:
400,000,000 common shares, par value $0.001 per share
Issued and outstanding:
124,503,297 common shares (September 30, 2014 - 47,200,237)		124,503			47,201
Additional paid-in capital		72,949,380			52,078,750
Common stock to be issued		777,415			640,000
Accumulated deficit		(61,777,951	)		(52,573,325	)
Total stockholders' equity		12,073,347			192,626
Total liabilities and stockholders' equity	$	13,182,668		$	7,353,502